RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Examples of efficacy from dose escalation studiesTheir past history!!!
They are a company with 2 products on the market that do NOT generate enough money to make the company profitable!
Just recently, they became a R&D company with those 2 other possibilities.
One with the old Egrifta, years on the market and just now research for NASH??, and a molecule from the deal with Katana, very early in the proces!
So it is obvious the market says: "wait and see......".
Plus they (BOD) have no vested intrest, so they don't care about the shareprice (proof the "ONO" ................), despite the "ridiculously low shareprice"???????!!!
After all those years again living in HOPE..........
SPCEO1
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Examples of efficacy from dose escalation studies First, let me say t hat I think Palin is just flat out wrong that the market is giving value for NASH. The only analyst who has incorporated anything into their model for NASH is Mackie and they have very little influence over the stock price. The NASH KOL generated nothing for the stock. THTX's NASH entry is just not getting any respect from investors, largely because of t he backdoor way they got to this place but also because they are somewhat flailing around at the moment looking for financing. The risk of THTX doing another awful financing because Paul is insisting on moving ahead with NASH is likely hurting the stock price right now so it might be argued NASH is taking value away from the stock rather than adding value to it. Consider if you were an investor who was very interested in THTX's intriguing cancer program but the CEO keeps talking about how committed he is to fund its NASH program. You might be hesitant to step in front of that Mack truck of another low-ball share offering to fund the thing you are not interested in right? Especially since Paul and the board already have a bad track record of acting foolishly with regard to an offering.
Now, I actually think their NASH program is very viable and stands as good a chance as any other program to be a meaningful player in what could turn out to be a large NASH market in the latter half of this decade. I think their NASH program is likely worth more than the current market cap of THTX if THTX could figure out a way to get the market to buy into it. The only way I see that happening is by essentially bribing Wall Street with high fees on corporate banking deals to get their backing. It may be disgusting but it would likely be effective and it would have a lot of other benefits as well (notably better analyst coverage). And if there is no way to crystalize the value in NASH, then I sure don't want to have another foolish share offering loaded on legacy shareholders backs if management is unable to convince either potential partners or other investors that what they have in NASH is legit. If I am right and what THTX has in NASH is legit, they should be able to convince other investors that is correct. But if Paul never draws attention to the huge valuation disparity between THTX and its NASH program and other similarliy situated NASH stocks, he is not only failing as a CEO but also has little chance of pulling off a proper funding of the NASH program.
I ask again, what is wrong with this and who is going to fix it:
THTX market cap - $356 million
Taimed market cap (Trogarzo only) - $733 million
CYDY market cap (a complete joke of a company) - $1.18 billion
IVA market cap (NASH only)- $578 million
AKRO market cap (NASH only) - $773 million
PRLD market cap (phase 1a cancer only) - $1.49 billion
This is how the market is valuing these companies. Why is it that THTX is always on the short end of the stick when it has Trogarzo, Egrifta for lipo, NASH and cancer??????
You might argue the market is overvaluing all those others and you would not get a big argument about that from me. But if the market is willing to overvalue them, there is no reason I can see why THTX should not tap into that overly bullish sentiment, especially since they are looking for funding for NASH.